Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Study May Explain Why Once-Promising Cancer Drugs Failed

By Duke University | January 24, 2019

Invading cells (green) in the lab worm C. elegans (purple) can change their tactics to get around cancer drugs called MMP inhibitors and trespass into other tissues. The findings may point to better ways to block cancer’s spread. Credit: Images courtesy of Laura Kelley, Duke University.

Nearly two decades after a class of once-promising cancer drugs called MMP inhibitors mysteriously failed in clinical trials, scientists think they may have an explanation for what went wrong.

The findings in C. elegans worms could lead to better ways to prevent the first steps of metastasis, the spread of the disease responsible for 90 percent of cancer deaths.

MMP inhibitors were aimed at blocking a group of enzymes long thought key to cancer’s spread. Called matrix metalloproteinases, the enzymes help dissolve the tough outer membrane that surrounds both tumors and healthy tissues, allowing cancer cells to escape from their original locations and set up shop in other organs.

Yet despite promising results in mice, MMP inhibitors didn’t help people with cancer live longer and some patients developed serious side effects.

The new findings, from a team led by biology professor David Sherwood at Duke University, suggest that invasive cells switch to brute force and build a battering ram when their dissolving enzymes aren’t available.

The study will appear online January 24 in the journal Developmental Cell.

To metastasize, a tumor cell must first penetrate a dense sheet-like mesh of proteins and other molecules called the basement membrane, which surrounds tissues like a Kevlar wrapper.

Sherwood and his team study a similar process in transparent 1-millimeter worms, which — unlike human tumors — allow researchers to watch invading cells in action.

Normal worm cells use their MMP enzymes to help cut through the matrix of proteins in the basement membrane like molecular scissors, the researchers say. But cells in “knockout” worms lacking the MMP enzymes instead build a large protrusion that pummels and smashes its way through with brute force, said research scientist Laura Kelley, who led the experiments.

Normally the invading cell pushes through a narrow hole, “kind of like the escape tunnel in ‘The Shawshank Redemption,'” Sherwood said. “But in knockout worms it’s more like the Kool-Aid Man when he busts through walls.”

The researchers also found that the protrusion is filled with stiff networks of actin filaments for a harder-hitting punch. To fuel the blows, the cell also moves mitochondria — the power plants of the cell — to the site of the ram.

The team also developed a screening technique that enabled them to identify and target a mitochondrial gene that invasive cells rely on in the absence of MMPs, and were able to prevent the cells from breaking through.

The researchers hope their work in worms will identify drug targets that could one day be tested in combination with MMP inhibitors to better treat metastasis in humans.

If researchers can develop drugs that inhibit both MMP enzymes and the battering rams, they may be able to more effectively block cell invasion and keep cancer from spreading.


Filed Under: Oncology

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer 
Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia
oncopeptides
Oncopeptides’ Pepaxti wins positive opinion from CHMP for multiple myeloma patients
DNA sequencer
Localizing next-generation sequencing testing for cancer patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50